The collaboration revenue from net sales of zurzuvae was $36.1 million for the full year 2024 and $13.8 million for the first ...

SUPN inks deal to acquire Sage Therapeutics for up to $795 million, securing rights to depression drug Zurzuvae.

Sage Therapeutics shares gained 0.4% to trade at $9.11 on Tuesday. These analysts made changes to their price targets on Sage ...

Calm returned to Wall Street on Monday, and U.S. stocks rose, while oil prices gave back some of their initial spurts ...

Calm returned to Wall Street on Monday, and U.S. stocks rose, while oil prices gave back some of their initial spurts following Israel’s attack on Iranian nuclear and military targets at the end of ...

Big Pharma executives have not been shy about their desire for deals, but companies have been battling macro headwinds ...

The S&P 500 climbed 0.9% to reclaim most of its drop from Friday. The Dow Jones Industrial Average rose 317 points, or 0.8%, ...

Calm returned to Wall Street on Monday, and U.S. stocks rose, while oil prices gave back some of their initial spurts ...

The Nasdaq climbed 1.52% to 19,701.21, and the Dow Jones added 0.8%, closing at 42,515.09, supported in part by gains across the banking sector.

Supernus Pharmaceuticals (Nasdaq: SUPN) is to buy Sage Therapeutics (Nasdaq: SAGE) for total consideration of around $795 million. Shares in Sage shot up by 35% amid the news by midday Monday, while ...

Rowley Law PLLC is investigating potential securities law violations by Sage Therapeutics, Inc. (NASDAQ: SAGE) and ...

The S&P 500 climbed 0.9% to reclaim most of its drop from Friday. The Dow Jones Industrial Average rose 317 points, or 0.8%, ...